Related Experiment Video

Updated: Mar 31, 2026

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

2.4K

Drug safety evaluation of lenvatinib for thyroid cancer

Jolanta Krajewska1, Aleksandra Kukulska1, Barbara Jarzab1

  • 1a Nuclear Medicine and Endocrine Oncology Department , M.Sklodowska-Curie Memorial Cancer Center and Institute of Oncology , Gliwice Branch, Gliwice , Poland.

Expert Opinion on Drug Safety
|October 21, 2015
PubMed
Abstract

Insights

Lenvatinib, a targeted therapy, demonstrated improved progression-free survival in thyroid cancer patients. While side effects like hypertension and diarrhea occurred, they were generally manageable with dose adjustments, allowing continued treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Lenvatinib is an oral multitargeted tyrosine kinase inhibitor impacting VEGFR, FGFR, PDGFR, RET, and KIT signaling.
  • It has shown efficacy in radioiodine-resistant differentiated thyroid cancer (DTC), significantly improving progression-free survival compared to placebo (18.3 vs. 3.6 months).

Purpose of the Study:

  • To review the safety profile of lenvatinib in patients with differentiated thyroid carcinoma (DTC) and medullary thyroid carcinoma.
  • To assess the manageability of lenvatinib-related adverse events and their impact on treatment continuation.

Main Methods:

  • Analysis of published clinical trial data from Phase II and III studies.
  • Focus on safety and efficacy of lenvatinib in thyroid cancer treatment.

Main Results:

  • Common adverse events include hypertension, proteinuria, diarrhea, decreased appetite, weight loss, nausea, and stomatitis.
  • Dose reduction was necessary in 35-68% of patients, but only 15% discontinued treatment due to toxicity.

Conclusions:

  • Lenvatinib presents an acceptable safety profile for thyroid carcinoma treatment.
  • Adverse events are typically manageable through dose modification or supportive care, emphasizing the importance of early toxicity detection for sustained therapeutic benefit.
Keywords:
E7080differentiated thyroid cancerlenvatinibtyrosine kinase inhibitor

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

2.4K

Related Concept Videos

Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The...
9.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
522